Chromosome t(7;11)(p15;p15) translocation in acute myeloid leukemia coexisting with multilineage dyspoiesis and mutations in NRAS and WT1: A case report and literature review

Oncology Letters
Jingke YangMei Deng

Abstract

The chromosomal translocation t(7;11)(p15;p15) and the resulting nucleoporin 98-homeobox A9 (NUP98-HOXA9) gene fusion is rare but recurrent genetic abnormity in acute myeloid leukemia (AML). The present study describes a case of AML plus maturation (-M2) with multilineage dyspoiesis in a 30-year-old male in whom a 46,XY,t(7;11)(p15;p15) karyotype was detected through chromosome analysis. Subsequent molecular and sequencing analysis demonstrated a NUP98-HOXA9 fusion gene with a type I fusion between NUP98 exon 12 and HOXA9 exon 1b, and mutations in neuroblastoma V-Ras oncogene homolog and Wilms tumor 1. The patient achieved hematological complete remission (CR) following two courses of induction chemotherapy. However, the NUP98-HOXA9 fusion gene remained detectable during the hematological CR period and following intensive consolidation chemotherapy. The disease relapsed 11 months after diagnosis, and the patient became refractory, with complications from an infection causing eventual mortality. The present case and literature review suggest that patients with AML and t(7;11) may have unique biological and clinical characteristics, and a poor prognosis.

References

Jan 15, 1986·Cancer Genetics and Cytogenetics·T IshiharaY Yokoyama
Apr 1, 1984·Cancer Genetics and Cytogenetics·K Ohyashiki
Sep 1, 1982·Jinrui idengaku zasshi. The Japanese journal of human genetics·T TomiyasuM Okada
Jan 1, 1996·Cancer Genetics and Cytogenetics·T InabaM Nakagawa
Mar 10, 2001·Genes, Chromosomes & Cancer·H G AhujaM L Slovak
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Ajeeta B DashD Gary Gilliland
Jul 26, 2002·International Journal of Hematology·Keiki KawakamiHiroshi Shiku
Apr 11, 2006·Nuclear Receptor Signaling·Angie L Bookout, David J Mangelsdorf
Apr 2, 2009·American Journal of Hematology·Yoko MizoguchiKazuko Hamamoto
Aug 3, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Rashmi Kanagal-ShamannaKeyur P Patel
Mar 10, 2016·Journal of Clinical Medicine·Jennifer N Saultz, Ramiro Garzon
Jun 3, 2016·Haematologica·Raajit Rampal, Maria E Figueroa
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay

❮ Previous
Next ❯

Methods Mentioned

BETA
chromosomal aberrations
transgenic
MDS

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.